Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.

Lancet
Johanne SilvainALPHEUS investigators

Abstract

Percutaneous coronary intervention (PCI)-related myonecrosis is frequent and can affect the long-term prognosis of patients. To our knowledge, ticagrelor has not been evaluated in elective PCI and could reduce periprocedural ischaemic complications compared with clopidogrel, the currently recommended treatment. The aim of the ALPHEUS study was to examine if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective PCI. The ALPHEUS study, a phase 3b, randomised, open-label trial, was done at 49 hospitals in France and Czech Republic. Patients with stable coronary artery disease were eligible for the study if they had an indication for PCI and at least one high-risk characteristic. Eligible patients were randomly assigned (1:1) to either ticagrelor (180 mg loading dose, 90 mg twice daily thereafter for 30 days) or clopidogrel (300-600 mg loading dose, 75 mg daily thereafter for 30 days) by use of an interactive web response system, and stratified by centre. The primary outcome was a composite of PCI-related type 4 (a or b) myocardial infarction or major myocardial injury and the primary safety outcome was major bleeding, both of which were evalu...Continue Reading

References

Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Nov 17, 2009·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PLATFORM Investigators
May 17, 2011·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Dmitriy N FeldmanS Chiu Wong
Aug 28, 2012·The New England Journal of Medicine·Matthew T RoeUNKNOWN TRILOGY ACS Investigators
Sep 11, 2012·Journal of the American College of Cardiology·Kristian ThygesenDaniel R Wagner
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
Sep 3, 2013·The New England Journal of Medicine·Gilles MontalescotUNKNOWN ACCOAST Investigators
Feb 13, 2016·Journal of the American College of Cardiology·Dominick J AngiolilloRoxana Mehran
Mar 30, 2016·JAMA : the Journal of the American Medical Association·Robert W YehUNKNOWN DAPT Study Investigators
Apr 16, 2016·Journal of the American College of Cardiology·Usman BaberStuart Pocock
Jan 25, 2018·European Heart Journal·Michel ZeitouniUNKNOWN ACTION Study Group
Dec 21, 2018·Circulation·Kristian ThygesenUNKNOWN Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American He
Mar 2, 2019·Journal of the American College of Cardiology·Johanne SilvainUNKNOWN ACCOAST Investigators
Dec 13, 2019·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Yuehua LiDerek J Hausenloy
May 31, 2020·American Heart Journal·Johanne SilvainUNKNOWN ALPHEUS study group
Sep 4, 2020·Journal of the American College of Cardiology·Giuseppe TarantiniUNKNOWN Italian Society of Interventional Cardiology

❮ Previous
Next ❯

Citations

Feb 9, 2021·European Heart Journal·Giovanna Liuzzo, Carlo Patrono
Jan 23, 2021·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Mattia LunardiYoshinobu Onuma
Jan 16, 2021·European Heart Journal·Fernando AlfonsoJavier Escaned
Mar 3, 2021·JAMA : the Journal of the American Medical Association·Seng Chan YouHarlan M Krumholz
Feb 20, 2021·JACC. Cardiovascular Interventions·Michel Zeitouni, Paul Guedeney
May 12, 2021·Current Opinion in Cardiology·Mattia Galli, Dominick J Angiolillo
May 18, 2021·Expert Review of Clinical Pharmacology·Mattia GalliDominick J Angiolillo
Oct 9, 2021·European Heart Journal·Thomas F LüscherStavros V Konstantinides

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.